Effect of omeprazole, lansoprazole, and ranitidine on the dna synthesis of mononuclear cells

Tom E. Peddicord, Keith M. Olsen, Dean S. Collier

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To examine and compare the effects of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of peripheral blood mononuclear cells. Design: Ex vivo laboratory study. Setting: Clinical research laboratory of an academic medical center. Subjects: Healthy volunteers. Interventions: None. Measurements and Main Results: Venous blood was collected from normal subjects and peripheral blood mononuclear cells (PBMCs) were isolated using centrifugation techniques over a Ficoll-Hypaque density gradient. PBMCs were added to 12-well culture plates in four groups of media: a) control; b) control plus lansoprazole (25 μg/mL); c) control plus omeprazole (0.35 μg/mL); and d) control plus ranitidine (50 μg/mL). PBMCs were exposed to the drug for 96 hrs, with addition of phytohemagglutinin (2.5 μg/mL) for the last 48 hrs, and 3H-thymidine (1 μCi) during the final 6 hrs. PBMCs were filtered onto glass-fiber filter paper and the radioactivity was determined by scintillation counting. Since radioactivity is measured only in those cells undergoing DNA synthesis or cell division, results are expressed as quantification of 3H-thymidine uptake. Median disintegrations per min (DPM)/number of PBMCs per well ± SEM are reported: control 68.3 ± 37.8; ranitidine 38.4 ± 94.2; lansoprazole 14.6 ± 84.4; and omeprazole 15.1 ± 48.9. There was a significant difference between lansoprazole vs. ranitidine (p < .01), and omeprazole vs. ranitidine (p < .05), and no significant difference between lansoprazole and omeprazole. Conclusions: This is the first study to compare the potential immunomodulating effects of these commonly used agents. Ranitidine caused increased DNA synthesis in PBMCs when compared with lansoprazole and omeprazole. This phenomenon may be an important, often disregarded, effect of histamine-2-receptor antagonists when used in postsurgical or trauma patients who have T-lymphocyte-mediated immune suppression.

Original languageEnglish (US)
Pages (from-to)90-94
Number of pages5
JournalCritical care medicine
Volume27
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Lansoprazole
Ranitidine
Omeprazole
Blood Cells
Thymidine
Radioactivity
DNA
Diatrizoate
Histamine Receptors
Scintillation Counting
Ficoll
Phytohemagglutinins
Centrifugation
Cell Division
Healthy Volunteers
T-Lymphocytes
Wounds and Injuries
Research

Keywords

  • Critical care
  • Lansoprazole
  • Lymphoblastogenesis
  • Mononuclear cells
  • Omeprazole
  • Ranitidine
  • Stress-ulcer prophylaxis
  • Surgery
  • Thymidine
  • Trauma

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Effect of omeprazole, lansoprazole, and ranitidine on the dna synthesis of mononuclear cells. / Peddicord, Tom E.; Olsen, Keith M.; Collier, Dean S.

In: Critical care medicine, Vol. 27, No. 1, 01.01.1999, p. 90-94.

Research output: Contribution to journalArticle

@article{9ebb2b0fe3f84421a3feae7940420037,
title = "Effect of omeprazole, lansoprazole, and ranitidine on the dna synthesis of mononuclear cells",
abstract = "Objective: To examine and compare the effects of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of peripheral blood mononuclear cells. Design: Ex vivo laboratory study. Setting: Clinical research laboratory of an academic medical center. Subjects: Healthy volunteers. Interventions: None. Measurements and Main Results: Venous blood was collected from normal subjects and peripheral blood mononuclear cells (PBMCs) were isolated using centrifugation techniques over a Ficoll-Hypaque density gradient. PBMCs were added to 12-well culture plates in four groups of media: a) control; b) control plus lansoprazole (25 μg/mL); c) control plus omeprazole (0.35 μg/mL); and d) control plus ranitidine (50 μg/mL). PBMCs were exposed to the drug for 96 hrs, with addition of phytohemagglutinin (2.5 μg/mL) for the last 48 hrs, and 3H-thymidine (1 μCi) during the final 6 hrs. PBMCs were filtered onto glass-fiber filter paper and the radioactivity was determined by scintillation counting. Since radioactivity is measured only in those cells undergoing DNA synthesis or cell division, results are expressed as quantification of 3H-thymidine uptake. Median disintegrations per min (DPM)/number of PBMCs per well ± SEM are reported: control 68.3 ± 37.8; ranitidine 38.4 ± 94.2; lansoprazole 14.6 ± 84.4; and omeprazole 15.1 ± 48.9. There was a significant difference between lansoprazole vs. ranitidine (p < .01), and omeprazole vs. ranitidine (p < .05), and no significant difference between lansoprazole and omeprazole. Conclusions: This is the first study to compare the potential immunomodulating effects of these commonly used agents. Ranitidine caused increased DNA synthesis in PBMCs when compared with lansoprazole and omeprazole. This phenomenon may be an important, often disregarded, effect of histamine-2-receptor antagonists when used in postsurgical or trauma patients who have T-lymphocyte-mediated immune suppression.",
keywords = "Critical care, Lansoprazole, Lymphoblastogenesis, Mononuclear cells, Omeprazole, Ranitidine, Stress-ulcer prophylaxis, Surgery, Thymidine, Trauma",
author = "Peddicord, {Tom E.} and Olsen, {Keith M.} and Collier, {Dean S.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1097/00003246-199901000-00032",
language = "English (US)",
volume = "27",
pages = "90--94",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of omeprazole, lansoprazole, and ranitidine on the dna synthesis of mononuclear cells

AU - Peddicord, Tom E.

AU - Olsen, Keith M.

AU - Collier, Dean S.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective: To examine and compare the effects of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of peripheral blood mononuclear cells. Design: Ex vivo laboratory study. Setting: Clinical research laboratory of an academic medical center. Subjects: Healthy volunteers. Interventions: None. Measurements and Main Results: Venous blood was collected from normal subjects and peripheral blood mononuclear cells (PBMCs) were isolated using centrifugation techniques over a Ficoll-Hypaque density gradient. PBMCs were added to 12-well culture plates in four groups of media: a) control; b) control plus lansoprazole (25 μg/mL); c) control plus omeprazole (0.35 μg/mL); and d) control plus ranitidine (50 μg/mL). PBMCs were exposed to the drug for 96 hrs, with addition of phytohemagglutinin (2.5 μg/mL) for the last 48 hrs, and 3H-thymidine (1 μCi) during the final 6 hrs. PBMCs were filtered onto glass-fiber filter paper and the radioactivity was determined by scintillation counting. Since radioactivity is measured only in those cells undergoing DNA synthesis or cell division, results are expressed as quantification of 3H-thymidine uptake. Median disintegrations per min (DPM)/number of PBMCs per well ± SEM are reported: control 68.3 ± 37.8; ranitidine 38.4 ± 94.2; lansoprazole 14.6 ± 84.4; and omeprazole 15.1 ± 48.9. There was a significant difference between lansoprazole vs. ranitidine (p < .01), and omeprazole vs. ranitidine (p < .05), and no significant difference between lansoprazole and omeprazole. Conclusions: This is the first study to compare the potential immunomodulating effects of these commonly used agents. Ranitidine caused increased DNA synthesis in PBMCs when compared with lansoprazole and omeprazole. This phenomenon may be an important, often disregarded, effect of histamine-2-receptor antagonists when used in postsurgical or trauma patients who have T-lymphocyte-mediated immune suppression.

AB - Objective: To examine and compare the effects of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of peripheral blood mononuclear cells. Design: Ex vivo laboratory study. Setting: Clinical research laboratory of an academic medical center. Subjects: Healthy volunteers. Interventions: None. Measurements and Main Results: Venous blood was collected from normal subjects and peripheral blood mononuclear cells (PBMCs) were isolated using centrifugation techniques over a Ficoll-Hypaque density gradient. PBMCs were added to 12-well culture plates in four groups of media: a) control; b) control plus lansoprazole (25 μg/mL); c) control plus omeprazole (0.35 μg/mL); and d) control plus ranitidine (50 μg/mL). PBMCs were exposed to the drug for 96 hrs, with addition of phytohemagglutinin (2.5 μg/mL) for the last 48 hrs, and 3H-thymidine (1 μCi) during the final 6 hrs. PBMCs were filtered onto glass-fiber filter paper and the radioactivity was determined by scintillation counting. Since radioactivity is measured only in those cells undergoing DNA synthesis or cell division, results are expressed as quantification of 3H-thymidine uptake. Median disintegrations per min (DPM)/number of PBMCs per well ± SEM are reported: control 68.3 ± 37.8; ranitidine 38.4 ± 94.2; lansoprazole 14.6 ± 84.4; and omeprazole 15.1 ± 48.9. There was a significant difference between lansoprazole vs. ranitidine (p < .01), and omeprazole vs. ranitidine (p < .05), and no significant difference between lansoprazole and omeprazole. Conclusions: This is the first study to compare the potential immunomodulating effects of these commonly used agents. Ranitidine caused increased DNA synthesis in PBMCs when compared with lansoprazole and omeprazole. This phenomenon may be an important, often disregarded, effect of histamine-2-receptor antagonists when used in postsurgical or trauma patients who have T-lymphocyte-mediated immune suppression.

KW - Critical care

KW - Lansoprazole

KW - Lymphoblastogenesis

KW - Mononuclear cells

KW - Omeprazole

KW - Ranitidine

KW - Stress-ulcer prophylaxis

KW - Surgery

KW - Thymidine

KW - Trauma

UR - http://www.scopus.com/inward/record.url?scp=0032944871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032944871&partnerID=8YFLogxK

U2 - 10.1097/00003246-199901000-00032

DO - 10.1097/00003246-199901000-00032

M3 - Article

C2 - 9934899

AN - SCOPUS:0032944871

VL - 27

SP - 90

EP - 94

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1

ER -